WUPyV in Children with Acute Respiratory Tract Infections, China
To the Editor: WU polyomavirus (WUPyV) is a human polyomavirus fi rst detected in respiratory samples in 2007 (1) . It has since been detected worldwide (2-7), including the People's Republic of China (8) , but whether it is a causative respiratory pathogen remains speculative. To investigate the potential role of WUPyV in respiratory diseases and its prevalence in Tianjin, China, we examined samples obtained from children with upper respiratory tract infections (URTIs) and lower respiratory tract infections (LRTIs) by using PCR for the VP2 and LTAg genes, as described previously (1) . As a control, we also tested samples from patients who did not have respiratory diseases.
Case (Table) . Nasopharyngeal aspirate samples were collected from hospitalized children, and throat swabs were obtained from outpatients with URTIs and from control children.
Of the 174 nasopharyngeal aspirate specimens tested, 28 (16%) had WUPyV VP2 gene-positive fragments; 24 had LTAg gene-positive fragments. Four VP2-positive but LTAg-negative fragments were sequenced; nucleotide sequences were identical to WUPyV strains in GenBank. Mean age of WUPyV-infected patients was 11.7 months (range 12 days-39 months); 10 patients (36%) were <6 months of age, 10 (36%) were 6 months-1 year, 7 (25%) were 1-2 years, and 1 (4%) was 2-5 years of age. The age distribution was similar to that of the original cohort. We We detected WUPyV VP2 fragment-positive specimens by multi-PCR using the Seeplex RV Detection kit-1 (Seegene, Seoul, South Korea) for other respiratory viruses, including adenovirus, parainfl uenza viruses 1, 2, 3 (PIV1, 2, 3), infl uenza viruses A and B, rhinovirus (rhinovirus V), human metapneumovirus, respiratory syncytial virus A and B (RSV A, B), and coronaviruses OC43/HKU1 and 229E/NL63, according to the manufacturers' instructions. First strands of cDNA were produced by using the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Glen Burnie, MD, USA). Human bocavirus (HBoV) was tested as described previously (9) .
Twenty (71%) case-patients were co-infected with other respiratory viruses, most commonly RSV B (9/28, 32%), followed by HBoV (6/28, 21%), rhinovirus V and PIV3 (4 each of 28, 14%), human metapneumovirus (3/28, 11%), adenovirus and infl uenza A (2 each of 28, 7%), and 229E (1/28, 4%). Of 20 patients with co-infections, 14 (50%) were infected with 2 viruses; 2 (7%) with 3 viruses (WU, RSV B, PIV3; and WU, infl uenza virus, A, HBoV); 3 (11%), with 4 viruses (WU, RSV B, PIV3, infl uenza A; WU, RSV B, PIV3, HBoV; and WU, RSV B, rhinovirus V, HBoV); and 1 (4%), with 5 viruses (WU, RSV B, PIV3, BoV, rhinovirus V).
Three (4%) of 68 throat swabs from outpatients with URTIs were WUPyV positive, substantially lower than from inpatients with LRTIs. Among 3 WUPyV-positive casepatients, 2 were 2 years of age and 1 was 3. No WUPyV was detected in 43 control samples.
The prevalence of WUPyV in hospitalized children with acute respiratory tract infections in Tianjin was 16.1%, higher than 7.1% found in a study in the United States (3); 4.9% in Germany (4); 4.5% in Australia (5); 6.29% in Thailand (6); and 2.2% 
